Long-term Risks of CJC-1295 and Ipamorelin

The long-term health risks of CJC-1295 and ipamorelin are essentially unknown because there are no multi-year controlled studies tracking cancer, cardiovascular outcomes, or overall mortality in people using these compounds.134 The available human literature is mostly limited to early-phase pharmacology and short postoperative studies that describe short-term tolerability and hormone effects, not durable safety.134 That means long-term risk cannot be quantified from current clinical data.

CJC-1295 is a synthetic long-acting analogue of growth hormone-releasing hormone (GHRH) developed to prolong stimulation of pituitary growth hormone release.1 Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts through a ghrelin or GHRP-like receptor pathway rather than the GHRH receptor.23 Because the two agents act through different receptors but converge on the GH/IGF-1 axis, they are often discussed together despite having limited long-term human follow-up.

CJC-1295 increases endogenous growth hormone secretion through GHRH receptor signaling and produces sustained increases in GH and IGF-1 after subcutaneous dosing in healthy adults.1 Ipamorelin is a ghrelin-receptor agonist that triggers a growth hormone pulse and, in human volunteer pharmacokinetic-pharmacodynamic work, showed a short terminal half-life of about 2 hours with a single episode of GH release after infusion.3 Neither mechanism proves long-term harm, but both are relevant because prolonged or repeated exposure may shift circulating IGF-1 upward, and higher IGF-1 has been associated in epidemiologic work with higher risk of some cancers and with adverse outcomes at both extremes of the distribution.5

For CJC-1295, the main published human study is an early randomized, placebo-controlled dose-escalation program lasting 28 and 49 days in healthy adults.1 It found multi-day GH and IGF-1 elevation after dosing and reported no serious adverse reactions, but it did not address multi-year safety.1

For ipamorelin, published human evidence is also short-term. A pharmacokinetic-pharmacodynamic study in healthy male volunteers characterized acute GH responses after infusion, and a later proof-of-concept randomized trial in postoperative bowel resection patients found short-term use was well tolerated over up to 7 days.34 These studies support short-term tolerability in limited settings, not long-term safety in healthy users.

• Early-phase endocrine pharmacology focused on GH and IGF-1 responses.13
• Ghrelin-receptor agonism and postoperative gastrointestinal recovery in surgical patients.4
• Broader GH/IGF-1 biology, including how long-term signaling relates to cancer and mortality risk.5678

The central limitation is that there is no direct long-term safety dataset for chronic CJC-1295 or ipamorelin use in healthy adults.134 Existing studies are small, short, and designed around pharmacodynamic endpoints rather than cancer incidence, cardiovascular events, diabetes risk, or mortality.

Indirect evidence raises caution rather than certainty. In a large prospective cohort, higher circulating IGF-1 was associated with higher breast and prostate cancer risk, and mortality showed a U-shaped relationship across the IGF-1 distribution.5 Reviews of cancer biology also describe the GH-IGF-1 axis as relevant to cell proliferation, apoptosis resistance, and tumor signaling, while congenital IGF-1 deficiency syndromes such as Laron syndrome have been studied partly because of their unusually low cancer risk.6

Evidence from growth hormone therapy does not settle the question. A 2014 systematic review and meta-analysis, largely in people treated during childhood and adolescence, reported increased overall cancer incidence and increased risk of second neoplasms, while emphasizing important confounding and the need for better long-term studies.7 A later meta-analysis of childhood recombinant growth hormone therapy found no clear increase in standard cancer incidence overall but still identified second neoplasm risk as a concern.8 These populations are not equivalent to healthy adults using secretagogues, but they underscore that chronic manipulation of the GH/IGF-1 axis should not be assumed to be risk-free.

The most defensible conclusion is therefore narrow: current evidence suggests CJC-1295 and ipamorelin can appear tolerable in the short term, but their long-term risk profile remains unquantified, and any claim of proven long-term safety would go beyond the available evidence.134578

1. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536.
2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552.
3. Svensson TH, Tunek A, Castaigne JP, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(8):1279-1285. doi:10.1023/a:1018955126402.
4. Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. doi:10.1007/s00384-014-2030-8.
5. Mukama T, Srour B, Mergenthaler P, et al. IGF-1 and risk of morbidity and mortality from cancer, cardiovascular diseases, and all causes in EPIC-Heidelberg. J Clin Endocrinol Metab. 2023;108(10):e1092-e1105. doi:10.1210/clinem/dgad212.
6. Laron Z, Werner H. Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome. Endocr Relat Cancer. 2023;30(9):e220394. doi:10.1530/ERC-22-0394.
7. Deodati A, Baldini Ferroli B, Cianfarani S. Association between growth hormone therapy and mortality, cancer and cardiovascular risk: systematic review and meta-analysis. Growth Horm IGF Res. 2014;24(4):105-111. doi:10.1016/j.ghir.2014.02.001.
8. Cai H, Bao Y, Jiang L, et al. Association between recombinant growth hormone therapy and all-cause mortality and cancer risk in childhood: systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:864908. doi:10.3389/fendo.2022.864908.